Skip to main content
Premium Trial:

Request an Annual Quote

Not Much of a Choice, Anyway

With credit tight and investors skittish, a hostile takeover of Genentech by Roche might not be that big of a deal, says an article in the San Jose Mercury News. And in any case, it's possible Genentech employees won't have many options these days when it comes to finding other jobs. Amid all the talk is a concern that a buyout would result in a loss of Genentech's renowned culture of independence and creativity, and an exodus of employees. Derek Lowe thinks that it will probably end up being difficult at best. The atmosphere of the acquiring company is going to seep in no matter what, he says, and keeping things small is a definite plus when it comes to productivity in drug discovery. "Overall, it really does help to know that you really do have to deliver, that there's no net down there, no one waiting to cushion the blow. It doesn't make things fun, not necessarily, but it does make them more productive."

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.